Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
(NASDAQ: LTRN) Delayed: 3.88 -0.19 (4.67%)
Previous Close $4.07    52 Week High $ 
Open $4.05    52 Week Low $ 
Day High $4.12    P/E N/A 
Day Low $3.86    EPS $ 
Volume 133,051